Incomplete cross tolerance and multiple mu opioid peptide receptors.
about
Opioid-induced constipation: advances and clinical guidanceChanges in mouse mu opioid receptor Exon 7/8-like immunoreactivity following food restriction and food deprivation in ratsAnatomical and functional correlation of the endomorphins with mu opioid receptor splice variants.Molecular insights into mu opioid pharmacology: From the clinic to the bench.Opiate pharmacology and relief of pain.Generation of the mu opioid receptor (MOR-1) protein by three new splice variants of the Oprm gene.Targeting TRPV1 as an alternative approach to narcotic analgesics to treat chronic pain conditions.Mu-opioid receptor splice variants: sex-dependent regulation by chronic morphine.Differences between opioids: pharmacological, experimental, clinical and economical perspectivesOpioid rotation in clinical practice.The pharmacogenetics of analgesia: toward a genetically-based approach to pain management.Recent advances in the use of opioids for cancer painRole of morphine's metabolites in analgesia: concepts and controversies.Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration.Preclinical pharmacology and opioid combinations.Treating chronic pain: new knowledge, more choices.Development of medications for alcohol use disorders: recent advances and ongoing challenges.Genetic variability and clinical efficacy of morphine.The pharmacotherapy of chronic pain: a review.Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.Morphine-induced MOR-1X and ASF/SF2 Expressions Are Independent of Transcriptional Regulation: Implications for MOR-1X SignalingMethylnaltrexone mechanisms of action and effects on opioid bowel dysfunction and other opioid adverse effects.Opiate-agonist induced taste aversion learning in the Fischer 344 and Lewis inbred rat strains: evidence for differential mu opioid receptor activation.A systematic review of combination step III opioid therapy in cancer pain: an EPCRC opioid guideline project.Management of pain in the elderly at the end of life.Molecular physiology of enteric opioid receptors.Reduced expression of a novel mu-opioid receptor (MOR) subtype MOR-1B in CXBK mice: implications of MOR-1B in the expression of MOR-mediated responses.Pharmacological Management of Cancer-Related Pain.Indications for Opioid Antagonists.Opioids in Gastroenterology: Treating Adverse Effects and Creating Therapeutic Benefits.Alternative splicing determines the post-endocytic sorting fate of G-protein-coupled receptors.Opioid rotation with extended-release opioids: where should we begin?Pharmacokinetic modelling of morphine, morphine-3-glucuronide and morphine-6-glucuronide in plasma and cerebrospinal fluid of neurosurgical patients after short-term infusion of morphine.Breakthrough pain: the importance of baseline analgesic regimen with opioidsTwo cases of opioid rotation applied to patients with chronic pain.Bioinformatic analysis of the human mu opioid receptor (OPRM1) splice and polymorphic variants.Insights into the Role of Opioid Receptors in the GI Tract: Experimental Evidence and Therapeutic Relevance.Effects of transgene-mediated endomorphin-2 in inflammatory pain.Suppression of the morphine-induced rewarding effect in the rat with neuropathic pain: implication of the reduction in mu-opioid receptor functions in the ventral tegmental area.Selective upregulation of functional mu-opioid receptor splice variants by chronic opioids.
P2860
Q26765571-77761EA8-1908-4FED-90F5-1840F0CF771FQ28572082-27B307E0-57AD-4730-8D2F-3AC7808BF7ADQ30863898-D62C7356-D2B6-42D2-B3E1-E0AC552AE4D6Q33608286-91C22207-E3DA-491B-9C01-6F6BE14DE66EQ33650564-E54B1F89-FD48-4EE6-87EA-FFA4AE599C76Q33950375-609F1CBA-FB5D-4FB3-987E-92F16BE3E6BAQ33954651-27F62E0F-CCE7-4F4C-BCB6-4B3E2D49B505Q34143307-9E319B68-EFAE-4280-9DA3-CBFA7B19512CQ34272502-96AF3DA1-976C-46DC-A64C-C44C76BDB7ADQ34305249-430C37C4-0A59-418F-9C14-C18AEEFBDEB2Q34355220-26E2ECEA-7E76-41B7-934C-87B05E46BC40Q34418203-F32F1E56-61F7-440C-AA2C-33DCB0183AAAQ35594877-D0AE955D-26E8-4364-905B-A4BF133C9825Q35804222-5DF5A46E-6C6B-4AAA-8526-54CC8CCC5034Q35839130-6D44ED89-3DF3-4456-8E5A-707F51B154FEQ36093047-47D54BDD-2205-44BA-83EB-22045A66C8FBQ36150622-E73E6949-8DE9-4475-B818-363104549902Q36207969-17F4BE6E-6DEB-414A-B61A-B37DE02EC367Q36411163-3E1362ED-A7C0-47CC-B627-9592CF3911E1Q36591603-D7393EB0-9281-45FA-A893-A94B88C59C72Q36712009-FBA80DCB-BC13-4D07-8A12-67A9398FBEC5Q36823204-B0962794-E07F-4B5C-B892-EC203C6BBF54Q37364459-1F998577-FB1E-416C-82E7-FBE5CEA78872Q37895006-30C28E04-7823-44C9-B9ED-33B17EB4F61DQ37998511-11D461AB-A699-45AF-93FC-A5408B8474D5Q38248063-42E3D4CD-EF64-48AD-BB61-C0C2FC198EF5Q38346695-00379AF9-DD03-49AA-8294-678D5043D652Q38672359-9911C00F-0275-4161-972C-EB956A342B81Q38762441-300B0246-8DAC-430B-8719-7BE5ABE2B474Q38772298-A34C6F2B-A61D-4D2F-B545-E9FEDBE8BB2CQ39927610-BB2F3571-B3A3-40D1-8E28-A263FD60E64EQ40425662-FB2D9F66-451D-4830-83C8-3EA7A1ACACAAQ40614474-9E969952-0FD4-4EED-B41F-8BA6FA8E73EAQ41880809-4C673BBB-1FD3-4F23-90F1-2CBA3C6A75CCQ41888422-896C1680-C4FB-4BEB-8891-ACEBC96ADFA0Q42157294-3AD5B7EB-1805-486D-98C6-8911CEE05126Q43062074-3B67CD52-A4F3-4F35-A533-326685E4FCA2Q43161654-C96FD160-0C6F-4742-9506-565EFAF09C81Q44163235-6FA284A6-46D9-46D4-BC91-26E807D1AD1DQ44334406-8AB9EB7E-0724-4E22-B8DB-3A88E5814410
P2860
Incomplete cross tolerance and multiple mu opioid peptide receptors.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Incomplete cross tolerance and multiple mu opioid peptide receptors.
@ast
Incomplete cross tolerance and multiple mu opioid peptide receptors.
@en
type
label
Incomplete cross tolerance and multiple mu opioid peptide receptors.
@ast
Incomplete cross tolerance and multiple mu opioid peptide receptors.
@en
prefLabel
Incomplete cross tolerance and multiple mu opioid peptide receptors.
@ast
Incomplete cross tolerance and multiple mu opioid peptide receptors.
@en
P1476
Incomplete cross tolerance and multiple mu opioid peptide receptors.
@en
P2093
Pasternak GW
P356
10.1016/S0165-6147(00)01616-3
P577
2001-02-01T00:00:00Z